Форимтамиг

Rec. INN (наименование, зарегистрированное ВОЗ)

2649379-96-2

immunoglobulin G1-lambda/kappa with crossed domains, anti-[Homo sapiens GPRC5D (G protein-coupled receptor class C group 5 member D)] and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], humanized monoclonal antibody, bispecific, trivalent;
gamma-lambda heavy chain bispecific, anti-GPRC5D and anti-CD3E (VH-CH1-V-lambda-CH1-CH2-CH3) (1-672) [humanized VH anti-GPRC5D (Homo sapiens IGHV3-23*03 (91.8%) -(IGHD) -IGHJ4*01 (93.3%), CDR-IMGT [8.8.10] (26-33.51-58.97-106)) (1-117) -Homo sapiens IGHG1*01, G1m17 (CH1 K26>E (147), K119>E (213), K120 (214) (118-215), hinge 1-6 (216-221)) (118-221) -10-mer bis(tetraglycyl-seryl) linker (222-231) -Musmus/Homsap V-LAMDDA anti-CD3E (Mus musculus IGLV1*01 (81.2%) -IGLJ1*01 (100%)/Homo sapiens IGLV7-46*01 (80.0%) -IGLJ3*02 (100%), CDR-IMGT [9.3.9] (257-265.283-285.322-330)) (232-340) -2-mer biseryl linker (341-342) -Homo sapiens IGHG1*01, G1m17,1, G1v14-49 CH2 A1.3, A1.2, G114, G1v32 CH3 W22 (knob) (CH1 K120 (439) (343-440), hinge 1-15 (441-455), CH2 L1.3>A (459), L1.2>A (460), P114>G (554) (456-565), CH3 S10>C (579), D12 (581), L14 (583), T22>W (591) (566-670), CHS (671- 672)) (343-672)], (220-218')-disulfide with kappa light chain anti-GPRC5D (1'-218') [humanized V-KAPPA (Homo sapiens IGKV3-20*01 (83.8%) -IGKJ5*01 (91.7%), CDR-IMGT [10.3.9] (27-36.54-56.93-101)) (1'-111') -Homo sapiens IGKC*01 (98.1%), E12>R (127), Q13>K (128), Km3 A45.1 (157), V101 (195) (112'-218')], (445-232''')-disulfide with light chain with crossed VH anti-CD3E (1'''-232''') [humanized VH (Homo sapiens IGHV3-23*03 (87.0%) -IGHJ4*01 (86.7%), CDR-IMGT [8.10.16] (26-33.51-60.99-114)) (1'''-125''') -Homo sapiens IGKC*01 (99.1%), R1.4>A (126), T1.3>S (127), Km3 A45.1 (171), V101 (209) (126'''-232''')]; gamma1 heavy chain anti-GPRC5D (1''-447'') [humanized VH (Homo sapiens IGHV3-23*03 (91.8%) -(IGHD) -IGHJ4*01 (93.3%), CDR-IMGT [8.8.10] (26-33.51-58.97-106)) (1''-117'') -Homo sapiens IGHG1*01, G1m17,1, G1v14-49 CH2 A1.3, A1.2, G114, G1v33 CH3 S22, A24, V86 (hole) (CH1 K26>E (147), K119>E (213), K120 (214) (118''-215''), hinge 1-15 (216''-230''), CH2 L1.3>A (234), L1.2>A (235), P114>G (329) (231''- 340''), CH3 Y5>C (349), D12 (356), L14 (358), T22>S (366), L24>A (368), Y86>V (407) (341''-445''), CHS (446''- 447'')) (118''-447'')], (220''-218'''')-disulfide with kappa light chain anti-GPRC5D (1''''-218'''') [humanized V-KAPPA (Homo sapiens IGKV3-20*01 (83.8%) -IGKJ5*01 (91.7%), CDR-IMGT [10.3.9] (27-36.54-56.93-101)) (1''''-111'''') -Homo sapiens IGKC*01 (98.1%), E12>R (127), Q13>K (128), Km3 A45.1 (157), V101 (195) (112''''- 218'''')]; dimer (451-226'':454-229'':579-349'')-trisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

Поделиться этой страницей